ContractLicence and Distribution Agreement • April 4th, 2005 • Amarin Corp Plc\uk • Pharmaceutical preparations • England
Certain portions of this Exhibit have been omitted pursuant to a request for “Confidential Treatment” under Rule 24b-2 of the Securities and Exchange Commission. Such portions have been redacted and bracketed in the request and appear as [*] in the text of this Exhibit. The omitted confidential information has been filed with the Securities and Exchange Commission.
ContractLicence Agreement • April 4th, 2005 • Amarin Corp Plc\uk • Pharmaceutical preparations
Certain portions of this Exhibit have been omitted pursuant to a request for "Confidential Treatment" under Rule 24b-2 of the Securities and Exchange Commission. Such portions have been redacted and bracketed in the request and appear as [*] in the text of this Exhibit. The omitted confidential information has been filed with the Securities and Exchange Commission.
DATED SCARISTA LIMITED - AND - LAXDALE LIMITEDExclusive Patent And • April 4th, 2005 • Amarin Corp Plc\uk • Pharmaceutical preparations • England
ContractLicence and Distribution Agreement • April 4th, 2005 • Amarin Corp Plc\uk • Pharmaceutical preparations
Certain portions of this Exhibit have been omitted pursuant to a request for “Confidential Treatment” under Rule 24b-2 of the Securities and Exchange Commission. Such portions have been redacted and bracketed in the request and appear as [*] in the text of this Exhibit. The omitted confidential information has been filed with the Securities and Exchange Commission.
DATED LAXDALE LIMITED - AND - SCARISTA LIMITEDExclusive Patent And • April 4th, 2005 • Amarin Corp Plc\uk • Pharmaceutical preparations • England
AGREEMENTAgreement • April 4th, 2005 • Amarin Corp Plc\uk • Pharmaceutical preparations
This Agreement, made and entered into this 27th day of October, 1999 by and between NISSHIN FLOUR MILLING CO., LTD., a corporation duly organized and existing under the laws of Japan, having its principal place of business at 25, Kanda-Nishiki-cho 1-chome, Chiyoda-ku, Tokyo, Japan (hereinafter referred to as “NISSHIN”) and LAXDALE LIMITED, a corporation duly organized and existing under the laws of the United Kingdom, having its principal place of business at Kings Park House, Laurelhill Business Park, Polmaise Road, Stirling, UK FK7 9JQ, (hereinafter referred to as “LAXDALE”):
ContractLicence and Distribution Agreement • April 4th, 2005 • Amarin Corp Plc\uk • Pharmaceutical preparations • Stirling
Certain portions of this Exhibit have been omitted pursuant to a request for “Confidential Treatment” under Rule 24b-2 of the Securities and Exchange Commission. Such portions have been redacted and bracketed in the request and appear as [*] in the text of this Exhibit. The omitted confidential information has been filed with the Securities and Exchange Commission.
SETTLEMENT AGREEMENT BY AND BETWEEN VALEANT PHARMACEUTICALS INTERNATIONAL, AND AMARIN CORPORATION PLC ANDSettlement Agreement • April 4th, 2005 • Amarin Corp Plc\uk • Pharmaceutical preparations • California
This Settlement Agreement, made as of the 27th day of September 2004, by and between Valeant Pharmaceuticals International (“Valeant”) and Amarin Corporation plc and Amarin Pharmaceuticals Company Limited (together “Amarin”) (Valeant and Amarin collectively referred to as the “Parties”):
CLINICAL TRIAL AGREEMENTClinical Trial Agreement • April 4th, 2005 • Amarin Corp Plc\uk • Pharmaceutical preparations • New York
THIS Agreement is entered into on March 18th 2005 by and between AMARIN NEUROSCIENCE LIMITED, a limited company incorporated in Scotland with offices located at Kings Park House, Laurelhill Business Park, Stirling, UK, FK7 9PQ (“Sponsor”) and the UNIVERSITY OF ROCHESTER (“Institution”), a not-for-profit educational institution established under the laws of New York State, with business offices located at 5th Floor Hylan Building, RC Box 270140, Rochester, NY 14627.
